News Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-15 pm EDT			5-day change	1st Jan Change
0.4752 ^USD	-6.82%		-15.14%	-54.76%

Mar. 21	Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	CI
Mar. 21	Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer	Mar. 21	AQ
Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	Mar. 21	CI
Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024	Mar. 21	CI
Transcript : Evoke Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 14	AQ
Evoke Pharma, Inc. Provides Earnings Guidance for 2024	Mar. 14	CI
Evoke Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024	Mar. 07	AQ
Evoke Pharma Announces Closing of $7.5 Million Public Offering	Feb. 14	AQ
Evoke Pharma Prices Underwritten Public Offering	Feb. 09	MT
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million	Feb. 09	AQ
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray	Nov. 30	AQ
Evoke Pharma Says FDA Lists Latest US Patent for Gimoti in Orange Book	Nov. 27	MT
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent	Nov. 27	AQ
Evoke Pharma : Failure to Satisfy Listing Rule - Form 8-K	Nov. 22	PU
Evoke Pharma - United States Patent and Trademark Office Grants another Formulation Patent Covering GIMOTI	Nov. 15	AQ
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI	Nov. 14	AQ
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Evoke Pharma Reports Third Quarter 2023 Financial Results	Nov. 09	AQ
Evoke Pharma and EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide	Nov. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Summary

Filters